Genotypic and Phenotypic Characterization of Replication-Competent HIV-2 Isolated from Controllers and Progressors.
HIV-2
Tat
long-term non-progressors
transactivation
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
09 Nov 2023
09 Nov 2023
Historique:
received:
29
09
2023
revised:
03
11
2023
accepted:
07
11
2023
medline:
27
11
2023
pubmed:
25
11
2023
entrez:
25
11
2023
Statut:
epublish
Résumé
Although some individuals with HIV-2 develop severe immunodeficiency and AIDS-related complications, most may never progress to AIDS. Replication-competent HIV-2 isolated from asymptomatic long-term non-progressors (controllers) have lower replication rates than viruses from individuals who progress to AIDS (progressors). To investigate potential retroviral factors that correlate with disease progression in HIV-2, we sequenced the near full-length genomes of replication-competent viruses previously outgrown from controllers and progressors and used phylogeny to seek genotypic correlates of disease progression. We validated the integrity of all open reading frames and used cell-based assays to study the retroviral transcriptional activity of the long terminal repeats (LTRs) and Tat proteins of HIV-2 from controllers and progressors. Overall, we did not identify genotypic defects that may contribute to HIV-2 non-progression. Tat-induced, LTR-mediated transcription was comparable between viruses from controllers and progressors. Our results were obtained from a small number of participants and should be interpreted accordingly. Overall, they suggest that progression may be determined before or during integration of HIV-2.
Identifiants
pubmed: 38005913
pii: v15112236
doi: 10.3390/v15112236
pmc: PMC10675771
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Erasmus MC
ID : Vriendenfonds
Organisme : Aidsfonds
ID : 60804
Références
PLoS One. 2014 Jan 28;9(1):e86719
pubmed: 24489776
AIDS Res Hum Retroviruses. 1996 Jun 10;12(9):821-8
pubmed: 8738434
J Virol. 2004 May;78(10):5205-15
pubmed: 15113902
Virology. 2006 Sep 15;353(1):144-54
pubmed: 16814357
Nat Methods. 2022 Jun;19(6):679-682
pubmed: 35637307
J Virol. 2005 Feb;79(3):1686-700
pubmed: 15650194
Trends Pharmacol Sci. 2009 Dec;30(12):631-7
pubmed: 19837464
J Virol. 1995 Aug;69(8):4854-62
pubmed: 7609053
Front Immunol. 2019 Jul 24;10:1749
pubmed: 31396237
Retrovirology. 2008 Dec 11;5:112
pubmed: 19077215
mBio. 2017 Nov 28;8(6):
pubmed: 29184023
Nucleic Acids Res. 1990 Apr 11;18(7):1839-46
pubmed: 2186367
Int J Mol Sci. 2022 Nov 08;23(22):
pubmed: 36430221
J Virol. 2004 Jan;78(1):524-30
pubmed: 14671134
J Virus Erad. 2017 Jan 1;3(1):7-14
pubmed: 28275453
J Virol. 2020 Mar 17;94(7):
pubmed: 31915276
J Virol. 2000 Oct;74(19):9222-33
pubmed: 10982369
Lancet HIV. 2018 Nov 1;:
pubmed: 30392770
Curr Opin HIV AIDS. 2011 May;6(3):151-6
pubmed: 21378562
Retrovirology. 2013 Mar 05;10:27
pubmed: 23497283
AIDS. 1996 Dec;10(14):1649-55
pubmed: 8970685
J Virol. 2007 May;81(10):5325-30
pubmed: 17329334
Lancet HIV. 2018 Nov 1;:
pubmed: 30392769
EMBO J. 1987 Dec 1;6(12):3755-60
pubmed: 2828036
J Mol Biol. 2000 Sep 15;302(2):359-75
pubmed: 10970739
J Virol. 1998 May;72(5):4478-84
pubmed: 9557745
J Infect Dis. 1999 Oct;180(4):1116-21
pubmed: 10479138
J Exp Med. 2021 Dec 6;218(12):
pubmed: 34636876
J Virol. 2012 May;86(9):4906-20
pubmed: 22345473
J Virol. 1992 May;66(5):3183-7
pubmed: 1560543
Rev Med Virol. 2013 Jul;23(4):221-40
pubmed: 23444290
Science. 1994 Sep 9;265(5178):1587-90
pubmed: 7915856
J Gen Virol. 2006 Feb;87(Pt 2):411-418
pubmed: 16432029
Virus Evol. 2022 Aug 24;8(2):veac075
pubmed: 36533148
Trends Immunol. 2007 Dec;28(12):532-40
pubmed: 17981085
Methods Mol Biol. 2005;304:95-112
pubmed: 16061969
Expert Rev Vaccines. 2008 Apr;7(3):319-31
pubmed: 18393602
J Virol. 1989 Dec;63(12):5501-4
pubmed: 2479775
J Virol. 2000 Feb;74(3):1554-7
pubmed: 10627569
iScience. 2020 Jan 24;23(1):100758
pubmed: 31927483
Vaccine. 2010 May 26;28 Suppl 2:B60-7
pubmed: 20510746
Sci Transl Med. 2021 Dec 15;13(624):eabl4097
pubmed: 34910552
Science. 1997 Nov 14;278(5341):1295-300
pubmed: 9360927
Proc Natl Acad Sci U S A. 2015 Mar 24;112(12):E1480-9
pubmed: 25730868
Mol Membr Biol. 1999 Jan-Mar;16(1):57-65
pubmed: 10332738
Blood. 2013 May 23;121(21):4330-9
pubmed: 23558015
Proc Natl Acad Sci U S A. 2022 Feb 8;119(6):
pubmed: 35110411
Future Microbiol. 2006 Dec;1(4):427-33
pubmed: 17661633
PLoS One. 2011 Jan 20;6(1):e14548
pubmed: 21283793
Nucleic Acids Res. 1994 Oct 25;22(21):4405-13
pubmed: 7971271
J Virus Erad. 2023 Aug 29;9(3):100343
pubmed: 37701289
Front Microbiol. 2022 Mar 24;13:763039
pubmed: 35401460
Eur J Immunol. 2015 Aug;45(8):2232-42
pubmed: 26018465
J Antimicrob Chemother. 2021 Feb 11;76(3):639-647
pubmed: 33184634
J Biol Chem. 2001 Apr 20;276(16):13433-41
pubmed: 11278567
Retrovirology. 2010 May 19;7:46
pubmed: 20482865
Nature. 2020 Sep;585(7824):261-267
pubmed: 32848246
J Infect Dis. 1998 Mar;177(3):600-10
pubmed: 9498438
J Virol. 2001 Jun;75(12):5457-64
pubmed: 11356952
Viruses. 2023 Jun 13;15(6):
pubmed: 37376660
Nat Rev Dis Primers. 2023 Aug 17;9(1):42
pubmed: 37591865
Antiviral Res. 2010 Jan;85(1):295-302
pubmed: 19733595
Syst Biol. 2010 May;59(3):307-21
pubmed: 20525638